BCDA
What one share of BioCardia holds
Biological Products, (No Diagnostic Substances)
BioCardia’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.74 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.76 |
| Cash and investments | $0.27 |
| Book value | $0.18 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $1.03 | −$18.48 | — | −$9.90 | — | — |
| 2017 | $1.69 | −$43.54 | $0.48 | −$31.16 | — | — |
| 2018 | $2.20 | −$49.20 | $0.23 | −$39.17 | — | $11.74 |
| 2019 | $1.89 | −$39.09 | $0.39 | −$25.49 | — | $5.21 |
| 2020 | $0.21 | −$22.24 | $0.05 | −$18.37 | — | $17.65 |
| 2021 | $0.90 | −$11.19 | $0.10 | −$9.29 | — | $9.22 |
| 2022 | $1.14 | −$10.08 | $0.06 | −$9.00 | — | $3.65 |
| 2023 | $0.34 | −$8.19 | $0.01 | −$7.07 | — | −$1.02 |
| 2024 | $0.02 | −$2.90 | $0.00 | −$2.88 | — | $0.18 |
| 2025 | $0.00 | −$1.23 | $0.00 | −$1.12 | — | $0.08 |